68 studies on PT-141 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Verified Peptides | 15 | 99.71% | View COA → |
| Polaris Peptides | 10 | 99.73% | View COA → |
| Uther Peptide | 9 | 99.82% | View COA → |
| Hk Peptides | 8 | 99.82% | View COA → |
| Peptide Sciences | 8 | 99.74% | View COA → |
| Lilipeptide | 8 | 99.31% | View COA → |
| Qing Li Peptide | 7 | 99.72% | View COA → |
| Allen Biotechnology Co Abc | 7 | 98.88% | View COA → |
Recent certificates: #15379 (99.759%) · #14675 (99.9%) · #13280 (99.9%) · #13281 (99.9%) · #12574 (99.9%) · #12204 (99.985%)
Manufacturers with published third-party certificates of analysis for PT-141. Open a vendor to see every batch we've verified.
The theoretical assessment of bremelanotide's safety during breastfeeding provides crucial preliminary guidance for healthcare providers and lactating women with HSDD. This initial understanding suggests a potentially…
These findings underscore the persistent challenges in achieving optimal maternal vaccination coverage, which is vital for preventing serious infections in infants. Low vaccination rates mean more newborns are left vu…
This study underscores the critical role of OB-GYNs as trusted sources of information for pregnant patients regarding vaccination. While recommendation rates are high, the discrepancy between recommendation and direct…
The study revealed that the high-dose quadrivalent influenza vaccine provided significantly better protection compared to the standard-dose vaccine in the veteran population. Recipients of the high-dose vaccine experi…
Maternal Tdap vaccination provides crucial early and sustained protection against pertussis for infants, bridging the vulnerable gap before they can receive their own full course of vaccinations. This strategy offers …
This study provides compelling evidence that a well-designed, interactive web-based intervention can be a highly effective strategy for overcoming vaccine hesitancy and significantly improving maternal vaccine uptake.…
This research highlights the significant therapeutic potential of melanocortin peptides in addressing unmet medical needs. The development of MTI could offer a novel, preventative approach to skin cancer through induc…
This study is significant because it demonstrates that bremelanotide (PT-141) can effectively improve subjective sexual response in premenopausal women with SAD, addressing a major unmet medical need. By targeting mel…
This review underscores the melanocortin system as a promising, non-vascular target for treating erectile dysfunction, offering a novel mechanism of action distinct from existing therapies. The central action of MC4R …
This comprehensive review underscores the significant therapeutic potential of melanocortin receptor agonists as a novel class of treatments for both male and female sexual dysfunction. Unlike many existing therapies …
This review is crucial because it underscores the central role of the brain in female sexual function and dysfunction, shifting focus from purely peripheral or hormonal explanations. By consolidating evidence for CNS-…
This review highlights the untapped potential of targeting the central nervous system for treating sexual dysfunction, offering a complementary approach to existing peripheral treatments. By modulating key neurotransm…
This retraction highlights the critical importance of research integrity and transparency in scientific publishing. Unverified or fraudulent data can mislead future research and potentially harm patients if treatments…
This study provides compelling evidence that bremelanotide can be an effective "salvage" therapy for men with erectile dysfunction who do not respond to conventional PDE5 inhibitors like sildenafil. This finding addre…
This review highlights a paradigm shift in treating male sexual dysfunction, moving beyond peripheral mechanisms to target the central nervous system. By modulating neurohormones and neurotransmitters, these agents co…
This seminal review provides a critical roadmap for pharmaceutical companies, academic researchers, and policymakers involved in drug development. By elucidating the common challenges and success factors, it offers va…
The review identified nasal apomorphine and bremelanotide as the most promising centrally acting agents with significant potential for future approval in erectile dysfunction (ED) treatment. While several other agents…
This case report underscores the significant and potentially life-threatening risks associated with the use of unregulated substances like Melanotan II. It highlights that severe adverse events, such as rhabdomyolysis…
This review underscores the significant therapeutic potential of melanocortin receptor agonists as a novel class of drugs for treating a wide range of sexual dysfunctions. By targeting central neural pathways, these c…
This review significantly advances the understanding of Hypoactive Sexual Desire Disorder (HSDD) as a legitimate neurobiological condition, moving beyond purely psychological explanations. The identification of specif…
This study provides strong evidence that bremelanotide is a safe, effective, and well-tolerated treatment for female sexual dysfunctions in premenopausal women. The significant improvements in satisfying sexual events…
This review solidifies Flibanserin's role as the first and only non-hormonal medication specifically approved for HSDD in premenopausal women, offering a crucial therapeutic option where few existed. Its mechanism, pr…
This review significantly advances our understanding of the complex neurobiological underpinnings of female sexual desire, particularly the nuanced role of serotonin. By elucidating how different serotonergic pathways…
This comprehensive review is immensely valuable for clinicians, providing a structured and evidence-based framework for the accurate diagnosis and effective management of HSDD. By synthesizing current knowledge, it he…
Understanding the substantial placebo effect in FSD trials is critically important for designing more robust, statistically powerful, and accurate clinical studies in the future. This insight will help pharmaceutical …
This study provides crucial evidence supporting the efficacy and dose-response profile of bremelanotide as a potential treatment for HSDD. The identification of optimal dosing and significant responder rates suggest t…
The approval of bremelanotide represents a pivotal advancement in addressing a significant unmet medical need for women experiencing HSDD. Its unique profile as a self-administered, on-demand subcutaneous therapy offe…
This analysis underscores the accelerated integration and growing importance of TIDES in modern medicine. The significant increase in FDA approvals for these compounds, even amidst a general slowdown in overall drug a…
This ultra-sensitive analytical method represents a crucial advancement for bremelanotide research and the broader field of peptide therapeutics, enabling accurate pharmacokinetic profiling of potential oral formulati…
The development of reliable and valid patient-reported outcome measures is paramount for accurate diagnosis, effective treatment monitoring, and robust clinical research in conditions like HSDD. This study provides st…
This research highlights the critical role of advanced analytical techniques in combating the illegal trade of unapproved drugs, which often pose significant health risks to users. The successful identification of mel…
This research provides crucial insights into the neurobiological underpinnings of bremelanotide's efficacy, specifically highlighting its impact on brain reward circuitry and neurotransmitter systems. Understanding th…
This study provides invaluable real-world evidence regarding the positive patient experience and perceived effectiveness of Bremelanotide for HSDD in premenopausal women. The high rates of satisfaction and tolerabilit…
This re-analysis provides crucial independent validation, challenging the initial interpretation of bremelanotide's efficacy and highlighting the importance of rigorous scrutiny of drug trial data. The findings sugges…
This comprehensive review is crucial for healthcare providers, offering a consolidated and accessible resource for understanding and effectively managing HSDD in women. The emphasis on a holistic, individualized appro…
This critical analysis underscores the urgent need for reconsideration of regulatory decisions regarding these drugs, given their questionable efficacy. The findings highlight how politicized industry-sponsored advoca…
This comprehensive review underscores that Bremelanotide offers a valuable on-demand pharmacological option for premenopausal women struggling with acquired, generalized HSDD, addressing a significant unmet medical ne…
This extensive and consolidated safety analysis confirms Bremelanotide's generally favorable and manageable safety profile for the treatment of HSDD. The low discontinuation rate due to adverse events, despite the com…
This study provides crucial evidence that bremelanotide offers a consistently effective treatment option for a broad range of women suffering from HSDD, regardless of their age, menopausal status, or other key demogra…
This comprehensive review provides a vital resource for healthcare professionals, offering much-needed clarity on the diverse medical treatments available for Female Sexual Dysfunction (FSD). By clearly outlining spec…
This review highlights the growing but still limited pharmacotherapeutic options for FSDs, emphasizing the significant unmet medical need for millions of women globally. The emergence of non-hormonal treatments and a …
This review provides a strong evidence base for clinicians, confirming that pharmacologic interventions are safe and effective tools to improve sexual desire and satisfaction in individuals experiencing sexual dysfunc…
Free, no account — handy when you're working with PT-141.